Specializing in umbilical cord blood banking, this company provides stem cell storage and related services primarily in China. Investors monitor it as a key player in the growing regenerative medicine market, with recurring revenue from long-term storage contracts. Its operations face regulatory scrutiny due to the sensitive nature of biological materials.
No congressional trades have been disclosed for Global Cord Blood Corporation (CO) yet. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
No congressional trades found for this stock.